» Articles » PMID: 36813094

The Role of Nicotinic Receptors in Alcohol Consumption

Overview
Journal Pharmacol Res
Publisher Elsevier
Specialty Pharmacology
Date 2023 Feb 22
PMID 36813094
Authors
Affiliations
Soon will be listed here.
Abstract

The use of alcohol causes significant morbidity and mortality across the globe. Alcohol use disorder (AUD) is defined by the excessive use of this drug despite a negative impact on the individual's life. While there are currently medications available to treat AUD, they have limited efficacy and several side effects. As such, it is essential to continue to look for novel therapeutics. One target for novel therapeutics is nicotinic acetylcholine receptors (nAChRs). Here we systematically review the literature on the involvement of nAChRs in alcohol consumption. Data from both genetic and pharmacology studies provide evidence that nAChRs modulate alcohol intake. Interestingly, pharmacological modulation of all nAChR subtypes examined can decrease alcohol consumption. The reviewed literature demonstrates that nAChRs should continue to be investigated as novel therapeutics for AUD.

Citing Articles

Distinct Chrna5 mutations link excessive alcohol use to types I/II vulnerability profiles and IPN GABAergic neurons.

Tochon L, Henkous N, Besson M, Maskos U, David V Transl Psychiatry. 2024; 14(1):461.

PMID: 39505853 PMC: 11541707. DOI: 10.1038/s41398-024-03164-8.


Exploring the efficacy of cholinergic agents for the treatment of psychostimulant use disorder: a systematic review.

Salloum N, Chouchana M, Icick R, Bloch V, Daumas S, El Mestikawy S Psychopharmacology (Berl). 2024; 241(11):2205-2222.

PMID: 39432105 DOI: 10.1007/s00213-024-06696-5.


Disrupted brain state dynamics in opioid and alcohol use disorder: attenuation by nicotine use.

Zhang R, Yan W, Manza P, Shokri-Kojori E, Demiral S, Schwandt M Neuropsychopharmacology. 2023; 49(5):876-884.

PMID: 37935861 PMC: 10948795. DOI: 10.1038/s41386-023-01750-w.

References
1.
Wouda J, Riga D, De Vries W, Stegeman M, van Mourik Y, Schetters D . Varenicline attenuates cue-induced relapse to alcohol, but not nicotine seeking, while reducing inhibitory response control. Psychopharmacology (Berl). 2011; 216(2):267-77. PMC: 3121941. DOI: 10.1007/s00213-011-2213-8. View

2.
de Bejczy A, Lof E, Walther L, Guterstam J, Hammarberg A, Asanovska G . Varenicline for treatment of alcohol dependence: a randomized, placebo-controlled trial. Alcohol Clin Exp Res. 2015; 39(11):2189-99. DOI: 10.1111/acer.12854. View

3.
Steensland P, Simms J, Holgate J, Richards J, Bartlett S . Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, selectively decreases ethanol consumption and seeking. Proc Natl Acad Sci U S A. 2007; 104(30):12518-23. PMC: 1914040. DOI: 10.1073/pnas.0705368104. View

4.
Ericson M, Engel J, Soderpalm B . Peripheral involvement in nicotine-induced enhancement of ethanol intake. Alcohol. 2000; 21(1):37-47. DOI: 10.1016/s0741-8329(99)00099-3. View

5.
Kranzler H, Zhou H, Kember R, Smith R, Justice A, Damrauer S . Genome-wide association study of alcohol consumption and use disorder in 274,424 individuals from multiple populations. Nat Commun. 2019; 10(1):1499. PMC: 6445072. DOI: 10.1038/s41467-019-09480-8. View